Gottlieb Nomination Draws Positive Reviews, And Some Questions

March 17, 2017

The administration’s plan to nominate Scott Gottlieb as FDA commissioner drew generally positive reactions on Capitol Hill and from drugmakers — but also some concerns from other stakeholders over his strong industry ties.

PhRMA CEO Stephen Ubl said the group looks forward to working with Gottlieb to modernize the FDA approval process, and said his history as a physician would benefit the agency. Gottlieb previously served as an FDA deputy commissioner.

The Association of Clinical Research Organizations said it “applauds the thoughtful nomination,” and said it believes Gottlieb will strike the appropriate balance of encouraging innovation while ensuring the safety and efficacy of new drugs.

View today's stories